On April 28, 2021, the Fifth All Things Growth Conference co-sponsored by the Hangzhou Municipal People’s Government, the Zhejiang Provincial Committee of the China Democratic National Construction Association and the China Investment and Development Promotion Association was grandly opened at the Hangzhou International Expo Center. At the meeting, the Hangzhou Venture Capital Association On-site entrepreneurial service platform "WeiLian" jointly released the "2021 Hangzhou Unicorn & Quasi-Unicorn Enterprise List", and Chance Pharmaceutical has been on the list for three consecutive years (2019-2021).
Among the quasi-unicorn companies in Hangzhou in 2021, 47 companies in the medical and health field will rank first in all fields, accounting for more than one-fifth. This shows that the status of medical companies is very important.
Hangzhou Chance Pharmaceutical is a biopharmaceutical company that is entering the commercialization stage. The company was founded in 2015 by a group of passionate and experienced industry experts. The company is committed to using its unique inhaled drug delivery platform technology to develop and industrialize inhaled drugs for the treatment of respiratory and non-respiratory diseases. Chance re-entry on the list is both an honor and motivation.
Chance Pharmaceuticals will continue to dig into the field of inhaled medicines, and provide patients with innovative medicines that can improve their quality of life. In the days to come, Chance Pharmaceuticals will surely follow a firm footstep towards a future full of dreams and passion.